Real-World study tracks daily life impact of breast cancer therapy

NCT ID NCT06161922

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study follows 600 Chinese women with early-stage HER2-positive breast cancer to see how anti-HER2 treatment affects their quality of life over a year. Participants fill out questionnaires about physical, emotional, and social well-being. The goal is to understand real-world experiences beyond standard medical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand how anti-HER2 therapy affects daily life and well-being in early breast cancer patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. Results may not apply to other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Keda Yu

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.